What Can You Do About Hair Loss? Treatments, Procedures, and Supportive Options

Start with the cause

Once hair loss becomes visible, most people want to know what can actually be done about it. It’s a natural question, but the answer depends on the type of hair loss involved, how long it has been going on, and whether the goal is to slow the progression, reduce shedding, improve hair density, or create a fuller look. Some treatments are better documented and better understood thanothers, so a good plan usually starts with identifying the likely diagnosis and then selecting treatments that are appropriate for both the condition and the patient’s goals. [1–4]

Hair loss is not a single disease. It is a clinical problem with several possible causes, and treatments that are effective for one form of hair loss may be of little use for another. Androgenetic alopecia remains the most common type and therefore receives the most attention in most treatment discussions, but diffuse hair loss, inflammatory scalp disease, traction alopecia, autoimmune alopecia, and scarring alopecia do not behave the same way and should not be treated as if they do. [1,2]

That is why diagnosis still comes before treatment. In men, assessing male-pattern hair loss is often relatively straightforward once the pattern has been established. In women, the picture can be more complex. Female-pattern hair loss can be more heterogeneous, and the clinical evaluation may therefore be more extensive before a treatment is selected. This may mean that a doctor recommends blood tests—for example, to assess metabolism, iron status, or selected hormone-related factors—before or concurrently with treatment. This does not mean that all women need the same tests, but it does mean that the evaluation and treatment plan are not always the same for men and women. [1,2]

Topical minoxidil: the primary first-line treatment

Topical minoxidil remains one of the most established and widely used treatments for pattern hair loss in both men and women. It is well documented and plays a central role in treatment because it is readily available, familiar to clinicians, and relevant for both sexes. [1,3,5]

For patients, it is often helpful to know what “effective” means in practice. Across meta-analyses and randomized trials, topical minoxidil generally does not result in dramatic regrowth, but it can lead to a meaningful improvement in hair count over time. A systematic review and meta-analysis found that topical minoxidil resulted in an average increase of approximately 16.7 total hairs per cm² and 20.9 non-vellus hairs per cm² compared to placebo. The increase in non-vellus hair was greater than the increase in total hair, because the analysis of non-vellus hair captured both new visible hairs and existing finer hairs that thickened and were therefore classified as non-vellus during treatment. In men, 5% topical minoxidil was also clearly superior to 2% minoxidil in a 48-week study, with approximately 45% more hair growth at week 48. [3,5,6]

The exact mechanism of action is not fully understood, but in clinical use, minoxidil appears to help hair follicles remain in the growth phase longer and support the production of thicker and longer hair in affected areas. In practice, it is best understood as a treatment that can slow the progression of hair loss and support regrowth, rather than restoring the full density a person may have had in their younger years. [3,5]

Patients should also be aware that minoxidil requires patience. Visible improvement usually takes months, not weeks. Some people experience increased hair shedding early in treatment. This can be alarming, but it does not necessarily mean that the treatment is not working.

This early hair shedding is believed to reflect a change in the hair cycle. Minoxidil promotes the transition of hair follicles from the resting phase (telogen) to the growth phase (anagen). When this transition occurs, older telogen hairs are shed to make room for new hairs in active growth. This can temporarily increase visible hair shedding during the first few weeks of treatment.

In most cases, this phase is self-limiting and is followed by stabilization of hair loss and a gradual improvement in hair density over time. Similar temporary hair loss has also been observed with other treatments that affect the hair cycle. It is important to continue treatment, as the effect often diminishes if treatment is stopped. [3,5]

Oral minoxidil: used more frequently, but still selectively

Low-dose oral minoxidil is becoming increasingly common in specialist practice, particularly among patients who cannot tolerate topical treatment, have difficulty using it regularly, or have not experienced sufficient results. It has become an important addition to the treatment arsenal, but is still used off-label in many places and requires careful prescribing and thorough guidance. [7,8]

Oral minoxidil has also been studied in clinical trials. In a 24-week open-label study of men taking 5 mg daily, the average total hair count increased by approximately 26 hairs per cm² after 12 weeks and 35.1 hairs per cm² after 24 weeks. In a subsequent randomized clinical trial, oral minoxidil 5 mg daily was not overall superior to 5% topical minoxidil, but the two treatments showed approximately equal efficacy, and photographic assessment suggested greater improvement at the vertex in some patients receiving oral treatment. [7,8]

In women, low-dose oral minoxidil may also be a useful option for selected patients, but the decision should be tailored to the individual and supported by thorough counseling. For some, the main advantage is easier use and better adherence than with topical treatment. The downside is that unwanted hair growth outside the scalp is more common, and fluid retention, edema, changes in blood pressure, and other cardiovascular side effects must still be discussed, even though many people tolerate low doses well. [7,8]

Finasteride and dutasteride: key systemic alternatives, particularly in men

For men with androgenetic alopecia, finasteride remains one of the most well-established oral treatments. This is particularly important because it acts on the androgen-related process that drives pattern hair loss, rather than simply supporting the hair growth cycle. [1,3,9]

In practice, finasteride is generally considered one of the most effective, well-established non-surgical treatments for men with androgenetic alopecia. In meta-analytic comparisons with placebo, oral finasteride 1 mg daily has been associated with an increase of approximately 18.4 hairs per cm². Dutasteride appears to have an even stronger effect on the same signaling pathway, and in a randomized 24-week study, dutasteride 0.5 mg daily increased both hair count and hair width more than finasteride 1 mg daily. [3,9] Although dutasteride may result in greater hair growth in some patients, finasteride is generally chosen first because it is more established as a treatment for hair loss and has a longer regulatory and clinical history. Dutasteride is therefore used more often when finasteride has not produced an adequate response, or when a stronger off-label alternative is considered appropriate.

These medications also require thorough counseling. Side effects, including sexual side effects, must be discussed openly, and treatment choices should be tailored to the individual rather than taken lightly. This is particularly important in patient education, because oral treatments often inspire both high hopes and disproportionate fears. [4,9]

Women and Antiandrogen Therapy

For women, topical minoxidil remains one of the main treatments. For some women, other prescription treatments may also be appropriate, especially when hormones appear to play a role in hair loss. One of the best-known options is spironolactone, but the right choice depends on the individual and can be influenced by age, medical history, how well the treatment is tolerated, and whether pregnancy is a possibility. [2,10]

Because these treatments can affect hormones, safety is an important part of the assessment. Spironolactone should not be used during pregnancy, and women of childbearing age need reliable contraception if it is prescribed. The same applies—and in some ways even more so—to finasteride and dutasteride. This is one of the reasons why treatment plans for women are often more individualized than those for men, even when the diagnosis remains male-pattern hair loss. [1,2,10]

Topical finasteride, topical dutasteride, and combination therapies

Interest in topical finasteride and dutasteride has increased significantly, in part because they offer a more localized treatment of the scalp with less systemic exposure and fewer broad hormonal effects—which many patients are concerned about. Topical finasteride now has stronger clinical support than it did just a few years ago. In a Phase 3 randomized trial, topical finasteride significantly improved hair count in the target area compared with placebo after 24 weeks and performed roughly as well as oral finasteride, while systemic finasteride exposure and the reduction in serum DHT were much lower. [11]

Combination therapy with topical finasteride and minoxidil is also becoming more relevant in clinical practice. The rationale is that the two treatments work in different ways and can therefore complement each other. A 2020 meta-analysis found that combinations of finasteride and minoxidil were generally more effective than minoxidil alone, and more recent randomized studies generally support this finding, although not all short-term studies have shown a clear difference between the groups after 12 weeks. [12-14]

Topical dutasteride has also been studied, but the clinical evidence remains more limited and less standardized. [15,16] In practice, the combination of topical finasteride and minoxidil currently appears to be the most relevant option for patients who want a stronger topical treatment or who are reluctant to use oral medication. [12-14]

Procedure-Based Treatments

In addition to medical treatment, several procedures are also used in the specialist health care system. In most cases, they are used as a supplement to established treatments, not as a replacement. [1,2]

Platelet-rich plasma (PRP) is one of the most commonly used treatments for pattern hair loss. The evidence for PRP is promising, and a recent meta-analysis found that it improved hair density compared to a placebo. However, the results should be interpreted with some caution, as the studies varied widely in terms of how PRP was prepared, how it was administered, and how outcomes were measured. This means that PRP is a promising option in specialist practice, but it remains less standardized and less firmly established than the main medical treatments. [17]

Microneedling is also used more frequently, usually in combination with topical treatments rather than on its own. In simple terms, it is believed to stimulate repair signals in the scalp and may also help topical treatments work more effectively. In practice, it is most often used when a patient wants to build upon treatments such as minoxidil, not replace them. A recent meta-analysis found that microneedling combined with topical minoxidil improved total hair count more than minoxidil alone, although the effect on hair thickness was less pronounced. [18,19]

Mesotherapy is a skin and scalp treatment in which small amounts of active ingredients are injected into the superficial layers of the skin. It is widely discussed and used at some clinics, but the evidence remains limited, and studies vary considerably in terms of the substances used, treatment regimens, and techniques. Overall, mesotherapy may be beneficial for selected patients, but stronger evidence is still needed. [20]

Low-level light therapy (LLLT) uses red or near-infrared light delivered through devices such as caps, helmets, or combs. It is a non-invasive option that appeals to patients who prefer a device-based or at-home approach. Studies suggest that LLLT may improve hair growth in cases of pattern hair loss, and it may also be useful as part of a combination therapy with minoxidil. [3,21] In practice, LLLT is best viewed as a supportive option, particularly for patients who want a more comprehensive treatment plan.

Hair Transplant

Hair transplantation remains the most direct way to restore visible hair density in carefully selected patients with stable pattern hair loss and sufficient donor hair. In practice, a hair transplant redistributes existing permanent hair from one area of the scalp to another. It does not create new hair follicles, nor does it reverse the underlying biological process that initially caused the thinning. [1,2]

The two main methods are follicular unit transplantation (FUT) and follicular unit extraction (FUE). FUT involves removing a strip of skin, which usually leaves a linear scar, but can effectively yield a large number of grafts. FUE involves extracting follicular units one by one, which avoids a long linear scar but usually takes longer. With both methods, it is important to remember that this is still a redistribution of existing hair, so the appearance and density of the donor area must also be taken into account when planning for a good overall result. [1,2]

Careful patient selection and realistic expectations are crucial. In most cases, continued medical treatment after surgery is also necessary to achieve and maintain a natural-looking long-term result. [1,2,4]

Camouflage

There are various methods for concealing thinning hair, including hair fibers, volumizing products, and tinted scalp treatments. These can provide a meaningful cosmetic improvement for some people. [4]

Scalp Care and Non-Medical Treatments

In addition to medical treatments and procedures, a variety of non-medical approaches are also used to improve scalp comfort and hair quality and, in some cases, support hair growth by improving overall scalp health. Managing scalp irritation, seborrheic dermatitis when present, and repeated damage to the hair shaft can improve the environment in which hair grows.

A healthier and calmer scalp can also make other treatments easier to tolerate and simpler to continue over time. [2,4] One example is ketoconazole shampoo. Although it is best known as a treatment for dandruff, studies suggest that it may also support hair growth in cases of androgenetic alopecia, particularly when scalp inflammation or seborrheic dermatitis is present. It should primarily be considered a supportive option, not a substitute for the most well-established hair loss treatments. [29,30]

Herbal products, hair oils, and botanical formulations

Many patients are interested in herbal products and hair oils, either because they prefer more natural alternatives or because they want something that feels gentler and more cosmetic. The evidence varies considerably among the ingredients, and overall, these products have been studied far less than the most established medical treatments. Nevertheless, they are clearly relevant to many patients, and traditional use and natural origin are often important factors when people are choosing between treatment options. [22]

Botanical ingredients with the strongest evidence

Rosemary oil is one of the best-known botanical ingredients in this field and has garnered attention both because of its long history of traditional use and encouraging clinical data. In a randomized controlled trial, patients who used rosemary oil showed improvement over six months, with results comparable to those of 2% minoxidil in that study. This makes rosemary one of the more credible botanical alternatives for patients interested in a more natural approach, even though the evidence base is still less extensive than that for the most established medical treatments. [22,23]

Pumpkin seed oil also has supporting clinical evidence and is increasingly recognized as a relevant natural ingredient in hair care. The most important human study used an oral pumpkin seed oil supplement in men with androgenetic alopecia, not a topical hair oil, which is important to keep in mind when interpreting the results. Nevertheless, the findings are encouraging and support pumpkin seed oil as a promising option within a broader strategy for hair and scalp care. [22,24]

Botanical ingredients with a history of traditional use and a growing body of evidence

Amla has a long tradition in hair care and is attracting increasing clinical interest. A randomized study of an oral product containing amla fruit in women with female androgenetic alopecia contributes to this interest. Although this does not directly establish the efficacy of topical amla oil, it supports amla as a meaningful ingredient with both traditional relevance and growing scientific interest. [25]

Bhringraj, Eclipta alba or Eclipta prostrata, also has deep traditional roots in hair care. Current evidence comes primarily from preclinical studies, including animal models that suggest hair growth-promoting activity and beneficial effects on hair follicle biology. Taken together, this makes bhringraj a relevant traditional ingredient with encouraging early scientific support, although better studies in humans are still needed. [26,27]

Peppermint oil is in a similar position. The best-known evidence comes from animal studies rather than human studies, but it remains a well-known and scientifically interesting ingredient in hair care. For now, it is best viewed as a promising supportive alternative while clinical evidence in humans continues to be developed. [28]

Botanical ingredients used primarily to care for and support the scalp

Some oils should primarily be viewed as ingredients that nourish the scalp, rather than as direct hair growth treatments. This applies to ingredients such as avocado oil, sesame oil, harakeke seed oil, ungurahua or pataua oil, mamey sapote oil, caiaue or ojon oil, and kakadu plum oil. These ingredients can contribute to scalp comfort, conditioning, cosmetic benefits, and an improved overall scalp environment, which can still be highly relevant in hair and scalp care even when direct evidence of hair growth is limited. [22]

A similar principle applies to vitamins, minerals, and omega fatty acids included in hair care formulations. They may be particularly relevant in cases of deficiency, but they can also play a role as part of a broader supportive strategy and are often perceived as beneficial by patients who desire a more holistic and natural approach to hair and scalp health. [2,22]

Combination therapy is often a practical way forward

When treating hair loss, many patients choose to combine different approaches to increase the likelihood of a meaningful result. This may include topical treatment, oral treatment when appropriate, and sometimes procedures such as PRP or microneedling. [18,19,21]

Natural products can also play a role as part of a broader treatment plan. Their value often lies in their ability to make the scalp feel healthier and calmer, support overall scalp health, and make other treatments easier to tolerate over time. In this way, they can contribute to greater comfort, better adherence, and a more sustainable long-term plan. [2,4,22]

Set expectations early

One of the most important aspects of treatment is managing expectations. Hair loss progresses slowly, and visible improvement usually takes time. Many treatments are better at slowing the progression of hair loss and preserving existing hair than at restoring previous hair density. This is not a sign of treatment failure. It is simply a reflection of the biology behind hair loss and the rate at which the hair responds. [3-5]

Conclusion

Hair loss treatment is most effective when it begins with an accurate diagnosis and then adapts the intensity of treatment to the biology of the condition and the patient’s goals. Topical minoxidil remains a key first-line treatment; oral treatments such as finasteride and selected off-label alternatives play an important role; and procedures such as PRP, microneedling, mesotherapy, LLLT, and transplantation can be useful in appropriately selected patients. [1–5] Herbal products and hair oils can also play a valuable role, particularly for patients seeking more natural or scalp-supporting alternatives, and are best viewed as ingredient-specific treatments that can be integrated into a broader long-term plan. [22-28]

Sources

1. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men—short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.

2. Olsen EA. Hair Loss in Women. N Engl J Med. 2025;393(15):1509-1520.

3. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5.

4. Gregoire S, Mostaghimi A. Effective counseling of patients with hair loss. J Am Acad Dermatol. 2023;89(2S):S40-S42.

5. Gupta AK, Charrette A. Topical minoxidil: Systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13(3):185-189.

6. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.

7. Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb). 2020;10(6):1345-1357.

8. Penha MA, Miot HA, Kasprzak M, Ramos PM. Oral Minoxidil vs. Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605.

9. Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3.

10. Aleissa M. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Cureus. 2023;15(8):e43559.

11. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: A phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294.

12. Chen L, Zhang J, Wang L, et al. The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: A systematic review and meta-analysis. Aesthet Plast Surg. 2020;44(3):962-970.

13. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of a topical solution of 0.25% finasteride mixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257-2263.

14. Lubis FF, Legiawati L, Saulina M, Saldi SRF. Randomized controlled trial on the efficacy and safety of combination therapy with topical 0.1% finasteride and 5% minoxidil in male androgenetic alopecia. Arch Dermatol Res. 2025;317(1):691. doi:10.1007/s00403-025-04216-9.

15. Sanchez-Meza E, Ocampo-Candiani J, Gomez-Flores M, et al. Microneedling plus topical dutasteride solution for androgenetic alopecia: A randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022;36(10):e806-e808.

16. Andrade JFM, Verbinnen A, Bakst A, et al. Topical dutasteride for androgenic alopecia: Current status and prospects. Ther Deliv. 2025;16(3):271-283.

17. Kieling L, Konzen AT, Zanella RK, Valente DS. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials. An Bras Dermatol. 2024;99(6):847-862.

18. Abdi P, Awad C, Anthony MR, et al. Efficacy and safety of combination therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: A systematic review and meta-analysis. Arch Dermatol Res. 2023;315(10):2775-2785.

19. Gupta AK, Wang T, Bamimore MA, Ravi SP, Talukder M. Relative Effects of 5% Minoxidil, Platelet-Rich Plasma, and Microneedling in Pattern Hair Loss: A Systematic Review and Network Meta-Analysis. Skin Appendage Disord. 2023;9(6):397-406.

20. Beer J, Boghosian T, Mendez H, et al. Injectable therapy for androgenetic alopecia: A systematic review. Dermatol Surg. Jan. 28, 2026. doi:10.1097/DSS.0000000000004999. Published online ahead of print.

21. Kaiser MA, Almeida SM, Rodriguez M, et al. Low-Level Light Therapy and Minoxidil Combination Treatment in Androgenetic Alopecia: A Review of the Literature. Skin Appendage Disord. 2023;9(2):104-110.

22. Gupta AK, Talukder M, Bamimore MA. Natural products for male androgenetic alopecia. Dermatol Ther. 2022;35(4):e15323.

23. Panahi Y, Taghizadeh M, Tahmasbpour Marzony E, Sahebkar A. Rosemary oil vs. 2% minoxidil for the treatment of androgenetic alopecia: A randomized comparative trial. SKINmed. 2015;13(1):15-21.

24. Cho YH, Lee SY, Jeong DW, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: A randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:549721.

25. Akhbari M, Firooz A, Rahimi R, et al. The effect of an oral product containing amla fruit (Phyllanthus emblica L.) on female androgenetic alopecia: A randomized controlled trial. J Ethnopharmacol. 2024;318(Pt A):116958.

26. Datta K, Singh AT, Mukherjee A, et al. Eclipta alba extract with potential for promoting hair growth. J Ethnopharmacol. 2009;124(3):450-456.

27. Begum S, Lee MR, Gu LJ, et al. Exogenous stimulation with Eclipta alba promotes hair matrix keratinocyte proliferation and downregulates TGF-beta1 expression in nude mice. Int J Mol Med. 2014;35(2):496-502.

28. Oh JY, Park MA, Kim YC. Peppermint Oil Promotes Hair Growth without Toxic Effects. Toxicol Res. 2014;30(4):297-304.

29. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. doi:10.1159/000017954.

30. Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. Dermatol Ther. 2020;33(1):e13202. doi:10.1111/dth.13202.